Technical Analysis for SAR - Sareum Holdings Plc

Grade Last Price % Change Price Change
C 2.225 0.00% 0.00
SAR closed unchanged on Thursday, May 6, 2021, on 79 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical SAR trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
20 DMA Support Bullish 0.00%
Hammer Candlestick Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Doji - Bullish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Older End-of-Day Signals for SAR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day about 18 hours ago
3x Volume Pace about 22 hours ago
2x Volume Pace about 22 hours ago
1.5x Volume Pace about 22 hours ago
20 DMA Support about 22 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Sareum Holdings Plc Description

Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Chemistry Disease Radio Cancer Branches Of Biology Diseases Drugs Therapy Biology Blood Rtt Disorders Skills Autoimmune Diseases Cancers Enzymes Medicinal Chemistry Radiotherapy Arthritis Chemotherapy Kinase Acute Myeloid Leukemia Inflammatory Disorders Leukemia Psoriasis Rheumatoid Arthritis Tyrosine Kinase

Is SAR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.093
52 Week Low 0.5
Average Volume 9,501,107
200-Day Moving Average 1.56
50-Day Moving Average 1.88
20-Day Moving Average 2.12
10-Day Moving Average 2.25
Average True Range 0.17
ADX 25.88
+DI 20.59
-DI 19.78
Chandelier Exit (Long, 3 ATRs ) 1.93
Chandelier Exit (Short, 3 ATRs ) 2.17
Upper Bollinger Band 2.44
Lower Bollinger Band 1.80
Percent B (%b) 0.66
BandWidth 30.18
MACD Line 0.11
MACD Signal Line 0.11
MACD Histogram 0.0037
Fundamentals Value
Market Cap 72.71 Million
Num Shares 3.27 Billion
EPS -0.10
Price-to-Earnings (P/E) Ratio -22.25
Price-to-Sales 929.82
Price-to-Book 25.82
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.44
Resistance 3 (R3) 2.42 2.33 2.41
Resistance 2 (R2) 2.33 2.28 2.34 2.39
Resistance 1 (R1) 2.28 2.25 2.31 2.30 2.38
Pivot Point 2.19 2.19 2.20 2.20 2.19
Support 1 (S1) 2.14 2.13 2.16 2.15 2.07
Support 2 (S2) 2.05 2.10 2.05 2.06
Support 3 (S3) 1.99 2.05 2.04
Support 4 (S4) 2.01